Today John Cumbers talks to Ursheet Parikh, partner at Mayfield and leader of their biotechnology and health care portfolios. The conversation is about what it takes to scale synthetic biology companies, some of the challenges they face, and how platform technologies in synthetic biology can help float all boats. Ursheet is a proven repeat entrepreneur […]
The post Synthetic Biology Investing in an Age of Open Platforms appeared first on SynBioBeta.
Original Article: Synthetic Biology Investing in an Age of Open Platforms